Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat JC, Gonzalez-Calle V, Moreno DF, Cabañas V, Lopez-Muñoz N, Bartolome-Solanas A, Español-Rego M, Reguera-Ortega JL, Rosiñol L, Lopez-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EAA, Martínez-López J, Mateos MV, Tomas X, Setoain X, Fernández de Larrea C.
Zugasti I, et al. Among authors: juan m.
Blood Adv. 2024 Nov 27:bloodadvances.2024014360. doi: 10.1182/bloodadvances.2024014360. Online ahead of print.
Blood Adv. 2024.
PMID: 39602341